AU2007279261A1 - Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists - Google Patents

Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists Download PDF

Info

Publication number
AU2007279261A1
AU2007279261A1 AU2007279261A AU2007279261A AU2007279261A1 AU 2007279261 A1 AU2007279261 A1 AU 2007279261A1 AU 2007279261 A AU2007279261 A AU 2007279261A AU 2007279261 A AU2007279261 A AU 2007279261A AU 2007279261 A1 AU2007279261 A1 AU 2007279261A1
Authority
AU
Australia
Prior art keywords
egfr
antibody
antibodies
tumors
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007279261A
Other languages
English (en)
Inventor
Eric Rowinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of AU2007279261A1 publication Critical patent/AU2007279261A1/en
Assigned to IMCLONE LLC reassignment IMCLONE LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: IMCLONE SYSTEMS INCORPORATED
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007279261A 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists Abandoned AU2007279261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27
US60/833,487 2006-07-27
PCT/US2007/074448 WO2008014386A2 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Publications (1)

Publication Number Publication Date
AU2007279261A1 true AU2007279261A1 (en) 2008-01-31

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007279261A Abandoned AU2007279261A1 (en) 2006-07-27 2007-07-26 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists

Country Status (15)

Country Link
EP (1) EP2043688A4 (ko)
JP (1) JP2009544736A (ko)
KR (1) KR20090033841A (ko)
CN (1) CN101484186A (ko)
AU (1) AU2007279261A1 (ko)
BR (1) BRPI0712368A2 (ko)
CA (1) CA2654911A1 (ko)
CR (1) CR10486A (ko)
EA (1) EA200870603A1 (ko)
EC (1) ECSP089011A (ko)
MX (1) MX2008016187A (ko)
NO (1) NO20085182L (ko)
TN (1) TNSN08512A1 (ko)
WO (1) WO2008014386A2 (ko)
ZA (1) ZA200810600B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019167A2 (pt) * 2019-03-27 2021-12-21 Nat Res Council Canada Anticorpos anti-egfrviii e fragmentos de ligação a antígeno dos mesmos

Also Published As

Publication number Publication date
TNSN08512A1 (en) 2010-04-14
CN101484186A (zh) 2009-07-15
EP2043688A4 (en) 2009-11-11
WO2008014386A2 (en) 2008-01-31
EP2043688A2 (en) 2009-04-08
BRPI0712368A2 (pt) 2012-06-05
KR20090033841A (ko) 2009-04-06
CA2654911A1 (en) 2008-01-30
EA200870603A1 (ru) 2009-06-30
ZA200810600B (en) 2009-11-25
JP2009544736A (ja) 2009-12-17
MX2008016187A (es) 2009-01-20
WO2008014386A3 (en) 2008-07-03
NO20085182L (no) 2009-04-24
CR10486A (es) 2009-02-23
ECSP089011A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
RU2502523C2 (ru) АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ
JP5179702B2 (ja) 受容体Ｅｒｂ−Ｂ１に対する医薬組成物
JP6967853B2 (ja) ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
AU2006332212B8 (en) Combination therapy using anti-EGFR and anti-HER2 antibodies
CN102884084B (zh) 抗her2抗体及组合物
CN109071666A (zh) 人脊髓灰质炎病毒受体（pvr）特异性抗体
CN107708666A (zh) 治疗癌症的联合疗法
US20120201817A1 (en) Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
CN115768467A (zh) 用于治疗癌症和感染的针对NKp46的抗体及其构建体
US20220112283A1 (en) Antibodies specific to human nectin-2
AU2007279261A1 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
WO2008095015A2 (en) Method of treating recurrent tumors
KR20220153615A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN116333125A (zh) 结合死亡受体4和死亡受体5的抗体

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period